康众医疗(688607) - 2021 Q1 - 季度财报

Financial Performance - Operating revenue for the first quarter reached CNY 88,763,204.08, a 112.14% increase year-on-year[5] - Net profit attributable to shareholders surged by 836.00% to CNY 22,444,014.27 compared to the same period last year[5] - Basic earnings per share rose to CNY 0.28, reflecting a 600.00% increase year-on-year[7] - Total revenue for Q1 2021 reached ¥88,763,204.08, a significant increase of 112.5% compared to ¥41,841,807.86 in Q1 2020[28] - Net profit for Q1 2021 was ¥22,426,173.56, compared to ¥2,389,907.90 in Q1 2020, representing a substantial increase of 836.5%[30] - The company's operating revenue for Q1 2021 was ¥75,324,101.72, a 83.5% increase from ¥41,024,494.74 in Q1 2020[32] - The net profit for Q1 2021 reached ¥18,478,746.72, compared to ¥4,970,697.86 in Q1 2020, representing a 271.5% increase[33] Assets and Liabilities - Total assets increased by 110.25% to CNY 907,311,029.24 compared to the end of the previous year[5] - The company's total assets reached 907,311,029.24 RMB, compared to 431,546,055.04 RMB at the end of 2020[21] - Total current assets as of March 31, 2021, amounted to 868,164,467.12 RMB, a substantial increase from 396,478,661.72 RMB at the end of 2020[19] - The total liabilities as of March 31, 2021, were 69,064,208.52 RMB, up from 62,703,014.06 RMB at the end of 2020[21] - Total liabilities for Q1 2021 were ¥62,905,149.16, an increase from ¥58,861,354.62 in Q1 2020, reflecting a growth of 3.5%[25] - Current liabilities rose to 60,570,544.78 RMB, an increase of 3,025,891.12 RMB compared to the previous year[43] Shareholder Information - Net assets attributable to shareholders increased by 127.28% to CNY 838,225,581.34 compared to the end of the previous year[5] - The total number of shareholders reached 8,755 by the end of the reporting period[11] - The top shareholder, Changcheng Co., Ltd., holds 14.85% of the shares, totaling 13,089,380 shares[12] - Jianqiang Liu, a natural person, holds 14.54% of the shares, totaling 12,810,000 shares[12] - Shareholders' equity totaled ¥819,105,865.64 in Q1 2021, compared to ¥353,284,632.79 in Q1 2020, representing an increase of 132.5%[25] Cash Flow - The company reported a net cash flow from operating activities of CNY -4,232,062.58, compared to CNY 6,372,316.49 in the same period last year[5] - The net cash flow from operating activities for Q1 2021 was -4,232,062.58 RMB, a significant decrease compared to 6,372,316.49 RMB in Q1 2020[17] - The net cash flow from investing activities was -51,764,957.47 RMB, primarily due to the purchase of financial products exceeding redemptions[17] - The net cash flow from financing activities increased to 445,933,421.47 RMB, attributed to funds raised from the company's IPO[17] - The cash inflow from financing activities included 447,342,486.13 RMB from investment absorption, indicating strong investor confidence[39] Research and Development - Research and development expenses as a percentage of operating revenue decreased by 6.03 percentage points to 7.06%[7] - Research and development expenses for Q1 2021 were ¥6,262,597.54, compared to ¥5,477,112.68 in Q1 2020, indicating an increase of 14.3%[29] - The company incurred R&D expenses of ¥5,386,318.21 in Q1 2021, slightly up from ¥5,037,011.03 in Q1 2020, indicating a focus on innovation[32] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[30] - Future outlook includes potential market expansion strategies, although detailed projections were not provided in the conference call[47] - The company is exploring acquisition opportunities to enhance its market position, with a focus on strategic growth initiatives[47]